製品番号: HY-P0201

サブスタンスＰ

(別名: Substance P; Neurokinin P)

33 Cited Publications

カスタマーレビュー

Based on 33 publication(s) in Google Scholar

Substance P (Neurokinin P) is a CNS-penetrant neuropeptide, acting as a neurotransmitter and as a neuromodulator in the CNS. The endogenous receptor for substance P is neurokinin 1 receptor (NK1-receptor, NK1R).

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.52%
CAS 番号: 33507-63-0
分子式: C₆₃H₉₈N₁₈O₁₃S
分子量:1347.63

保管条件:

Sealed storage, away from moisture.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Substance P 構造式

CAS 番号: 33507-63-0

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 臨床実験
化学情報
Publications (33)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

NK1R	Human Endogenous Metabolite

Neurokinin Receptor アイソフォーム固有の製品をすべて表示 :

Endogenous Metabolite アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	0.6 nM Compound: SP	SP-induced [Ca2+] mobilization in CHO cells expressing human Tachykinin receptor 1 SP-induced [Ca2+] mobilization in CHO cells expressing human Tachykinin receptor 1	[PMID: 10794691]
CHO	EC₅₀	1 nM Compound: table 1	Compound was evaluated for the inhibition of IPs hydrolysis on intact CHO cells expressing the human tachykinin NK-1 receptor Compound was evaluated for the inhibition of IPs hydrolysis on intact CHO cells expressing the human tachykinin NK-1 receptor	[PMID: 9871768]
CHO	EC₅₀	793 nM Compound: Substance P	Compound was evaluated for concentration-dependent and oscillatory increase in [Ca2+], caused by activation of hNK3 receptors in CHO cells Compound was evaluated for concentration-dependent and oscillatory increase in [Ca2+], caused by activation of hNK3 receptors in CHO cells	[PMID: 9871763]
CHO	EC₅₀	8 nM Compound: table 1	Compound was evaluated for the inhibition of cAMP formation on intact CHO cells expressing the human tachykinin NK-1 receptor Compound was evaluated for the inhibition of cAMP formation on intact CHO cells expressing the human tachykinin NK-1 receptor	[PMID: 9871768]
CHO	IC₅₀	1.4 nM Compound: Substance P	Tested for binding affinity against human wild type NK1 receptor expressed in CHO cells, using [125]SP as radioligand. Tested for binding affinity against human wild type NK1 receptor expressed in CHO cells, using [125]SP as radioligand.	[PMID: 11052787]
CHO	IC₅₀	1.5 nM Compound: SP	Displacement of [125I]BH-SP from human recombinant NK1 receptor expressed in CHO cells after 90 mins Displacement of [125I]BH-SP from human recombinant NK1 receptor expressed in CHO cells after 90 mins	[PMID: 21421318]
CHO	IC₅₀	1.5 nM Compound: SP, substance P	Displacement of [125I]BH-SP to human recombinant NK1 receptor in CHO cells Displacement of [125I]BH-SP to human recombinant NK1 receptor in CHO cells	[PMID: 18554914]
CHO	IC₅₀	1.7 nM Compound: Substance P	Tested for binding affinity against Q165A mutant NK1 receptor expressed in CHO cells, using [125]SP as radioligand Tested for binding affinity against Q165A mutant NK1 receptor expressed in CHO cells, using [125]SP as radioligand	[PMID: 11052787]
CHO	IC₅₀	125 nM Compound: Substance P	Compound was evaluated for its ability to displace [3H]NKB binding in hNK3 receptors expressed in CHO cells Compound was evaluated for its ability to displace [3H]NKB binding in hNK3 receptors expressed in CHO cells	[PMID: 9871763]
HEK293	EC₅₀	0.6 nM Compound: SP	Agonist activity at wild type human NK1 receptor expressed in HEK293 cells assessed as increase in [3H]IP accumulation after 20 mins Agonist activity at wild type human NK1 receptor expressed in HEK293 cells assessed as increase in [3H]IP accumulation after 20 mins	[PMID: 22574973]
IM-9	IC₅₀	0.26 nM Compound: SP	Inhibitory activity against binding of [125I]Bolton-Hunter SP to tachykinin NK-1 receptor in human lymphoma IM9 cells. Inhibitory activity against binding of [125I]Bolton-Hunter SP to tachykinin NK-1 receptor in human lymphoma IM9 cells.	10.1016/0960-894X(95)00582-E
IM-9	IC₅₀	0.61 nM Compound: Substance P	Antagonist activity for Tachykinin receptor 1 as displacement of [3H]-Substance P in human IM-9 cells Antagonist activity for Tachykinin receptor 1 as displacement of [3H]-Substance P in human IM-9 cells	[PMID: 9871670]
LAD2	EC₅₀	0.68 μM Compound: Substance P	Effect on mast cell degranulation in human LAD2 cells assessed as CCL3 release measured after 2 hrs by Luminex bead based assay Effect on mast cell degranulation in human LAD2 cells assessed as CCL3 release measured after 2 hrs by Luminex bead based assay	[PMID: 34266235]

体外実験

The neuropeptide substance P (SP) that are mediated by the neurokinin 1 receptor (NK1-R) desensitize and resensitize, which may be associated with NK1-R endocytosis and recycling. SP and the NK1-R are internalized into the same clathrin immunoreactive vesicles, and then sorted into different compartments. SP is intact at the cell surface and in early endosomes, but slowly degraded in perinuclear vesicles. SP induces clathrin-dependent internalization of the NK1-R. The SP/NK1-R complex dissociates in acidified endosomes. SP is degraded, whereas the NK1-R recycles to the cell surface. SP induces internalization of the NK1-R both in transfected epithelial cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 33507-63-0
性状 Solid
分子量 1347.63
分子式 C₆₃H₉₈N₁₈O₁₃S
Color White to off-white
別名

Substance P; Neurokinin P
配列

Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2
シーケンスの短縮

RPKPQQFFGLM-NH2
Structure Classification
- Others
Initial Source
- Endogenous metabolite
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (33)

All Histological Imaging/StainingIn Vivo Efficacy StudyRT-PCRCell Imaging/Staining

Sort by:

Journal Impact Factor

Bioact Mater

Skin-mimetic bilayer hydrogel normalizes diabetic wound healing by orchestrating inflammatory cell dynamics: An early intervention strategy. [Abstract]

2026 Feb 16:61:258-271. PMID: 41737639
Cell Discov

Structural insights into neurokinin 3 receptor activation by endogenous and analogue peptide agonists. [Abstract]

2023 Jun 30;9(1):66. PMID: 37391393
Int J Biol Sci

Neuropeptide substance P attenuates colitis by suppressing inflammation and ferroptosis via the cGAS-STING signaling pathway. [Abstract]

2024 Apr 22;20(7):2507-2531. PMID: 38725846

Substance P purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2024 Apr 22;20(7):2507-2531. [Abstract]

Substance P (SP, 5 nmol/kg; i.v.; once daily for 6 days) alleviates pathological indexes in DSS-induced colitis mice. Representative images of H&E sections and histological score. Scale bar = 100 μm.

Substance P purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2024 Apr 22;20(7):2507-2531. [Abstract]

Substance P (SP, 5 nmol/kg; i.v.; once daily for 6 days) alleviates pathological indexes in DSS-induced colitis mice. Photographs of colon length.

Substance P purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2024 Apr 22;20(7):2507-2531. [Abstract]

Substance P (SP, 5 nmol/kg; i.v.; once daily for 6 days) alleviates pathological indexes in DSS-induced colitis mice. (Images spleen)

Substance P purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2024 Apr 22;20(7):2507-2531. [Abstract]

RT-qPCR assay of inflammatory cytokines (TNF-α, IL-1β, IL-6 and IL-8) in TNF-α-stimulated Caco-2 cells treated with/without Substance P (SP, 25, 50, and 100 nmol) for 24 h. Data are obtained from three independent experiments, and expressed as the mean ± SEM; n = 5-8.

Substance P purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2024 Apr 22;20(7):2507-2531. [Abstract]

Representative picture of JC-1 staining in TNF-α-treated Caco-2 cells incubated with Substance P (SP, 100 nmol) for 24 h.
Free Radic Biol Med

H2O2 enhances the spontaneous phasic contractions of isolated human-bladder strips via activation of TRPA1 channels on sensory nerves and the release of substance P and PGE2. [Abstract]

2023 Oct 5;209(Pt 1):1-8. PMID: 37802373
J Headache Pain

Comparison of gepant effects at therapeutic plasma concentrations: connecting pharmacodynamics and pharmacokinetics. [Abstract]

2024 Aug 28;25(1):141. PMID: 39198753
J Transl Med

The role of substance P in Th17/Treg imbalance and ocular surface damage in chronic allergic conjunctivitis. [Abstract]

2025 Dec 1;23(1):1367. PMID: 41327447
Cell Mol Gastroenterol Hepatol

Mast Cells Inhibit Stem Cell-driven Epithelial Repair in Inflammatory Bowel Disease via Suppressing Wnt/lrp6/β-Catenin Signaling Pathway. [Abstract]

2026;20(5):101741. PMID: 41616821
Prog Neurobiol

Sodium leak channel contributes to neuronal sensitization in neuropathic pain. [Abstract]

2021 Jul:202:102041. PMID: 33766679
J Invest Dermatol

MRGPRX2-Mediated Mast Cell Activation Promotes Malignant Progression of Cutaneous Squamous Cell Carcinoma through IL-17A Release. [Abstract]

2025 Nov 4:S0022-202X(25)03517-1. PMID: 41197765
J Invest Dermatol

The key role of CB1R in the sensory neurons to regulate psoriasiform skin inflammation and pruritus. [Abstract]

2023 May;143(5):812-821.e3. PMID: 36410425
Cell Prolif

MiR-34b/c-5p and the neurokinin-1 receptor regulate breast cancer cell proliferation and apoptosis. [Abstract]

2019 Jan;52(1):e12527. PMID: 30334298
Cells

Identification of Natural Compounds Triggering MRGPRX2-Mediated Calcium Flux and Degranulation in RBL-2H3 Cells. [Abstract]

2026 Feb 3;15(3):287. PMID: 41677650
Eur J Pharmacol

Salicylic acid inhibits Mas-related G protein-coupled receptor X2-mediated mast cell 2 activation and mitigates cutaneous pseudo-allergic reactions. [Abstract]

2025 Sep 24:178189. PMID: 41005604
Eur J Pharmacol

Effects of 101BHG-D01, a novel M receptor antagonism, on allergic rhinitis in animal models and its mechanism. [Abstract]

2023 Sep 15:955:175902. PMID: 37422119
FASEB J

Nitric Oxide Scavenging Alleviates Scar Pruritus by Inhibiting S-Nitrosylation of Transient Receptor Potential Channels and Limiting Calcium Influx. [Abstract]

2025 Jul 31;39(14):e70817. PMID: 40637249
iScience

Trigeminal nerve-derived substance P regulates limbal stem cells by the PI3K-AKT pathway. [Abstract]

2023 Apr 18;26(5):106688. PMID: 37187698
Sci Rep

Metapanax delavayi extract as a neurocutaneous modulator via CRHR1/POMC/MC1R signaling. [Abstract]

2026 Feb 9;16(1):7851. PMID: 41663512
Food Sci Nutr

Evaluation of the Effects of Chitin and Chitosan on Pseudo-Allergic Reaction by Inhibiting MRGPRX2 Activation. [Abstract]

2025 Sep 1;13(9):e70877. PMID: 40901656
J Immunol Res

A Substance P (SP)/Neurokinin-1 Receptor Axis Promotes Perineural Invasion of Pancreatic Cancer and Is Affected by lncRNA LOC389641. [Abstract]

2022 May 12;2022:5582811. PMID: 35600049
Mol Med Rep

Substance P prevents doxorubicin‑induced cardiomyocyte injury by regulating apoptosis and autophagy: In vitro and in vivo evidence. [Abstract]

2022 Feb;25(2):50. PMID: 34913064
Immunol Lett

Ursolic acid attenuates pseudo-allergic reactions via reducing MRGPRX2-mediated mast cell degranulation. [Abstract]

2024 Dec:270:106934. PMID: 39395727
Mol Biol Rep

Substance P modulates BMSCs migration for tissue repair through NK-1R/CXCR4/p-Akt signal activation. [Abstract]

2022 Mar;49(3):2227-2236. PMID: 35034285
J Am Soc Mass Spectrom

Wire Desorption Combined with Electrospray Ionization Mass Spectrometry: Direct Analysis of Small Organic and Large Biological Compounds. [Abstract]

2020 Jul 5. PMID: 32559077
J Radiat Res Appl Sci

2026 Apr 23;19(2):102400.
Reprod Sci

Exposure to Green Light-emitting Diodes Alleviates Endometriosis-associated Pain in Mice with Induced Deep Endometriosis. [Abstract]

2026 Mar 19. PMID: 41854839
Chin J Integr Med

Inhibitory Effects of Nardostachys Jatamansi DC. Volatile Oil on Psychological Factors SP/CORT-Induced Hyperpigmentation. [Abstract]

2025 Dec;31(12):1097-1104. PMID: 41342982
SSRN

2026 Jun 16.
SSRN

2025 Feb 24.
Authorea

2023 Aug 14.
Research Square Preprint

2021 Dec.
Research Square Preprint

2021 Sep.
Research Square Preprint

2021 Jul.
Chin J Comp Med

May 2018,Vol. 28. No. 5

溶剤 & 溶解度

体外:

H₂O : ≥ 20 mg/mL (14.84 mM)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.7420 mL

3.7102 mL

7.4204 mL

5 mM

0.1484 mL

0.7420 mL

1.4841 mL

10 mM

0.0742 mL

0.3710 mL

0.7420 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (1.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (1.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (1.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (277 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Grady EF, et al. Delineation of the endocytic pathway of substance P and its seven-transmembrane domain NK1 receptor. Mol Biol Cell. 1995 May;6(5):509-24. [Content Brief]

[2]. Zhang L, et al. MiR-34b/c-5p and the neurokinin-1 receptor regulate breast cancer cell proliferation and apoptosis. Cell Prolif. 2018 Oct 17:e12527. [Content Brief]

[3]. Chappa AK, et al. Characteristics of substance P transport across the blood-brain barrier. Pharm Res. 2006 Jun;23(6):1201-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	0.7420 mL	3.7102 mL	7.4204 mL	18.5511 mL
	5 mM	0.1484 mL	0.7420 mL	1.4841 mL	3.7102 mL
	10 mM	0.0742 mL	0.3710 mL	0.7420 mL	1.8551 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Substance P

33 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

サブスタンスＰ

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Neuronal Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

CNS-Penetrant Compound Library

Human Endogenous Metabolite Compound Library

Drug Repurposing Compound Library

Neurotransmitter Receptor Compound Library

Anti-Pancreatic Cancer Compound Library

Food-Sourced Compound Library

Peptide Library

Anti-Cancer Natural Product Library

Protein-protein Interaction Inhibitor Library

Human Metabolite Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Animal-Sourced Natural Product Library

Multi-Target Compound Library

Bioactive Compound Library Max

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Peptide Compound Library

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Neurotransmitter Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Endogenous Metabolite Library

Neuropeptide Library

Mass Spectrometry Human Metabolite Library

Antimicrobial Peptides Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

MedChemExpress（MCE）の使用を引用している文献 Substance P

Neurokinin Receptor アイソフォーム固有の製品をすべて表示

Endogenous Metabolite アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (33)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Substance P 関連分類

HY-P0201 関連分類